pulmonary – pharmaceutical daily

May 20, 2019 Off

Global pulmonary embolism therapeutics market to post 9% CAGR over next five years

The global pulmonary embolism therapeutics market is expected to post aCAGR of more than 9% during the period 2019-2023, according to thelatest market research report by Technavio.

February 9, 2017 Off

Pulmonary drug delivery devices market to reach $43.05 billion by 2024

By Dino Mustafić

The Global Pulmonary Drug Delivery Devices Market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.

January 28, 2017 Off

Swedish Vicore Pharma’s IPF candidate C21 becomes orphan drug in US

By Dino Mustafić

Vicore Pharma’s C21 drug for treating idiopathic pulmonary fibrosis (IPF) has officially became an orphan drug in the USA.